Methylene Blue (methylthioninium chloride) is, unusually for the VialTalk catalogue, neither a peptide nor a peptide analog — it is a small-molecule phenothiazine dye with more than 130 years of medical history, a well-characterised redox pharmacology, and a small but growing modern research literature on mitochondrial bioenergetics and CNS applications. This monograph lays out its chemical identity, redox-cycling mechanism, the published research record, and the considerations specific to a defined small molecule rather than a peptide.
Chemical identity and structure.
Methylene Blue is 3,7-bis(dimethylamino)-phenothiazin-5-ium chloride. Molecular formula C₁₆H₁₈ClN₃S, molecular weight 319.85 g/mol. It is a deeply blue crystalline solid in its oxidised form and colourless in its reduced (leuco) form; the colour change between oxidation states is the visible signature of its redox cycling. It is highly water-soluble, stable as a dry powder for extended periods, and supplied either as the chloride salt powder or as pre-formulated aqueous solutions. USP-grade pharmaceutical Methylene Blue is the reference quality standard — non-pharmaceutical grades (industrial dye, biological stain) carry contaminants, including heavy metals, that make them unsuitable for any research-model use that touches biology.
Mechanism of action.
Methylene Blue's pharmacology derives from its redox-cycling chemistry. At low concentrations it acts as an alternative electron carrier in the mitochondrial electron transport chain — bypassing complex I/III blockades by shuttling electrons directly to cytochrome c — and increases mitochondrial oxygen consumption and ATP production in experimental models. At higher concentrations the redox behaviour reverses and the compound becomes pro-oxidant — a biphasic profile that dominates the dose-response literature. Separately, it is a guanylate-cyclase inhibitor, a monoamine-oxidase A inhibitor at higher concentrations, and a nitric-oxide-synthase inhibitor at higher concentrations still. The MAO-A and NOS-inhibitor properties are the basis for both its CNS-research interest and its principal drug-interaction risk.
Research applications and the evidence base.
Methylene Blue has a long-established registered indication for methemoglobinemia (treatment of acquired methemoglobinemia, FDA-approved). Outside that indication, the modern research literature spans mitochondrial-bioenergetics models (in-vitro and rodent), CNS questions (Alzheimer's disease, depression — small early-phase clinical trials exist for both), septic-shock vasoplegia (off-label clinical use), urology (urinary tract antiseptic, historical), and ifosfamide-induced encephalopathy (registered off-label use). Published clinical trial data outside methemoglobinemia is sparse and mostly small-N early-phase work — the evidence base is far better than for most peptides in this catalogue, but still does not support routine clinical use outside the registered indication.
Research context.
Methylene Blue is the canonical mitochondrial-electron-shuttle research compound and the reference comparator for any small molecule proposed to act on mitochondrial bioenergetics. Researchers working on mitochondrial bioenergetics in CNS contexts typically use Methylene Blue as the positive-control reference; researchers working in peptide-only contexts encounter it as one of the few non-peptide compounds shared between research-vendor catalogues and registered pharmacy.
Storage and handling.
Methylene Blue powder is stable at room temperature when kept dry and protected from light. Aqueous solutions should be refrigerated (2–8 °C) and protected from light; solutions are colourfast and stable for extended periods at refrigerator temperature. The compound stains everything it contacts — including skin, plastic, and biological tissue. Splash protection during handling is non-optional.
Quality and COA considerations.
A meaningful COA must confirm USP-grade or equivalent pharmaceutical-grade purity, with explicit reporting of heavy-metal content (lead, arsenic, mercury) — industrial- and stain-grade Methylene Blue carries heavy-metal contaminants that pharmaceutical-grade does not. Identity should be confirmed by spectroscopy (the characteristic absorbance maximum at ~664 nm is the canonical identity check) and purity by HPLC (≥99% benchmark for pharmaceutical-grade). Sterility and endotoxin testing should be reported for any solution intended for injection-model use.
Research-use note: This monograph is an educational summary of the published research literature on Methylene Blue. The compound has a registered FDA indication for methemoglobinemia; outside that indication it is investigational. Methylene Blue interacts significantly with serotonergic drugs (risk of serotonin syndrome) through its MAO-A inhibition — this is a documented clinical risk and is the largest single safety consideration in any research context that overlaps human exposure. Nothing here is medical advice or a usage recommendation.
